FOSAPREPITANT FOR INJECTION 150 MG — DIN 02549379
FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 150 MG · JUNO PHARMACEUTICALS CORP. · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is FOSAPREPITANT FOR INJECTION?
FOSAPREPITANT FOR INJECTION 150 MG contains FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02549379, held by JUNO PHARMACEUTICALS CORP., supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 07-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FOSAPREPITANT FOR INJECTION used for?
Prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Other Antiemetics in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Other Antiemetics, across 4 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MERCK CANADA INC | 2 | 1 | EMEND IV | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 1 | 1 | FOSAPREPITANT FOR INJECTION | Sourceable in Canada |
| APOTEX INC | 1 | 0 | FOSAPREPITANT | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 150 mg fosaprepitant / vial. |
| Storage | Not explicitly detailed in the provided text snippet (refers to section 20), but typically requires refrigeration or controlled room temperature after reconstitution. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Other Antiemetics |
|---|---|
| ATC code | A04AD |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02549379 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2549379 |
| Brand name | FOSAPREPITANT FOR INJECTION |
| Generic / active ingredient | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 150 MG |
| Market authorization holder | JUNO PHARMACEUTICALS CORP. |
| Health Canada schedule | Prescription |
| ATC code | A04AD |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A04AD |
| Current status | MARKETED |
| Status date | 07-Aug-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
150 mg administered on Day 1 only as an IV infusion over 20–30 minutes, initiated approximately 30 minutes prior to chemotherapy, in combination with a 5-HT3 antagonist and dexamethasone.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to fosaprepitant, aprepitant, or polysorbate 80. Concurrent use with pimozide, terfenadine, astemizole, or cisapride due to CYP3A4 inhibition risk.
Warnings and precautions
Serious hypersensitivity/anaphylaxis; infusion site reactions (thrombophlebitis, necrosis); significant drug interactions (CYP3A4, warfarin, contraceptives); monitoring for neurotoxicity with ifosfamide.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| EMEND IV | 150 MG | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | 02363356 |
| EMEND IV | 115 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 02324679 |
| FOSAPREPITANT | 150 MG | POWDER FOR SOLUTION | APOTEX INC | APPROVED | 02436264 |
2 · Same class — other molecules in ATC A04AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nabilone | ACT NABILONE · APO-NABILONE · CESAMET · PMS-NABILONE · +2 more | 17 | 9 | Yes |
| Aprepitant | EMEND · EMEND TRI-PACK | 3 | 3 | Yes |
| Other Antiemetics | EMEND IV · FOSAPREPITANT · FOSAPREPITANT FOR INJECTION | 4 | 2 | Yes |
| Dronabinol | MARINOL · MARINOL CAP 10MG | 3 | 0 | Not in Canada |
| Scopolamine | SCOPOLAMINE HYDROBROMIDE INJECTION USP | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A04AA | Dolasetron · Granisetron · Ondansetron · Palonosetron · Palonosetron, Combinations | 151 | 64 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.